produced a recombinant MV (rMV-SLAMblind) that bound to Nectin-4 but not its original primary receptor SLAM; it also infected and suppressed the growth of subcutaneous xenograft models of various cancers, including breast cancers such as TNBC (77–80). Here, NECTIN4 is linked to breast carcinoma.